



1625
IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of)
HESSE et al.)
Serial No. 10,517,263)
Filing or 371(c) Date: December 7, 2004)
For: PREPARATION OF BUTANEDIOL)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on May 23, 2005.

Typed or printed name of person signing this certificate: Sabine Berg

Signature: 


Honorable Commissioner for Patents
Alexandria, Virginia 22313-1450

SUBMISSION

Applicants enclose a copy of an English translation of the International Preliminary Examination Report.

Please charge any shortage in fees due in connection with the filing of this paper to Deposit Account No. 14.1437. Please credit any excess fees to such account.

Respectfully submitted,
NOVAK DRUCE DeLUCA & QUIGG LLP



Jason D. Voight
Reg. No. 42,205

Customer No. 26474
1300 Eye Street, N.W.
Suite 400 East
Washington, D.C. 20005
(202) 659-0100

Translation

PATENT COOPERATION TREATY

PCT/EP2003/006062



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference B02/0276PC	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP2003/006062	International filing date (<i>day/month/year</i>) 10 June 2003 (10.06.2003)	Priority date (<i>day/month/year</i>) 11 June 2002 (11.06.2002)
International Patent Classification (IPC) or national classification and IPC C07C 29/149		
Applicant BASF AKTIENGESELLSCHAFT		

<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>4</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of _____ sheets.</p>	
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>	

Date of submission of the demand 02 December 2003 (02.12.2003)	Date of completion of this report 04 February 2004 (04.02.2004)
Name and mailing address of the IPEA/EP	Authorized officer
Facsimile No.	Telephone No.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP2003/006062

I. Basis of the report

1. With regard to the **elements** of the international application:*

- ☐ the international application as originally filed
- ☒ the description:
pages _____ 1-25 _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☒ the claims:
pages _____ 1-28 _____, as originally filed
pages _____, as amended (together with any statement under Article 19
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the drawings:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the sequence listing part of the description:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets/fig _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/06062

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

I. Statement

Novelty (N)	Claims	1-28	YES
	Claims		NO
Inventive step (IS)	Claims	1-28	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-28	YES
	Claims		NO

2. Citations and explanations

The present application relates to a method for producing optionally alkylated 1,4-butanediol by two-stage catalytic hydrogenation in the gas phase of C4-carboxylic acids or derivatives thereof, by introduction of a gas flow of C4-carboxylic acid or a derivative into a first reaction zone and hydrogenation to a product flow containing γ -butyrolactone, which is converted to optionally alkylated 1,4-butanediol by gas-phase hydrogenation in a second reaction zone. The catalyst consists of ≤ 95 wt.% CuO and ≥ 5 wt.% oxidic support.

US-A-5 196 602 (D1) represents the closest prior art and differs from the subject matter of the present application in that the catalyst system consists of Ru, Ni, Pd, Fe, Co, Rh, Os, Ir, Pt, Zn and Cd, but not CuO, and, in addition, does not have an oxidic support.

The technical problem is therefore considered that of providing a further method for producing optionally alkylated 1,4-butanediol.

The solution is presented in claim 1. The use of the special catalyst system which is used in both the first and second reaction zones for the gas-phase hydrogenation of the C4 carboxylic acid to γ -butyrolactone and from γ -butyrolactone to 1,4-butanediol is rated as non-obvious ^{to} ~~by~~

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/EP 03/06062

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	1-28	YES
	Claims		NO
Inventive step (IS)	Claims	1-28	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-28	YES
	Claims		NO

2. Citations and explanations

The present application relates to a method for producing optionally alkylated 1,4-butanediol by two-stage catalytic hydrogenation in the gas phase of C4-carboxylic acids or derivatives thereof, by introduction of a gas flow of C4-carboxylic acid or a derivative into a first reaction zone and hydrogenation to a product flow containing γ -butyrolactone, which is converted to optionally alkylated 1,4-butanediol by gas-phase hydrogenation in a second reaction zone. The catalyst consists of ≤ 95 wt.% CuO and ≥ 5 wt.% oxidic support.

US-A-5 196 602 (D1) represents the closest prior art and differs from the subject matter of the present application in that the catalyst system consists of Ru, Ni, Pd, Fe, Co, Rh, Os, Ir, Pt, Zn and Cd, but not CuO, and, in addition, does not have an oxidic support.

The technical problem is therefore considered that of providing a further method for producing optionally alkylated 1,4-butanediol.

The solution is presented in claim 1. The use of the special catalyst system which is used in both the first and second reaction zones for the gas-phase hydrogenation of the C4 carboxylic acid to γ -butyrolactone and from γ -butyrolactone to 1,4-butanediol is rated as non-obvious to